Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized, double-blind, placebo-controlled oxytocin dose-response trial in children with Prader-Willi syndrome
2017-003423-30Phase 2Active
- Sponsor
- Dutch Growth Research Foundation
- Start
- Oct 2017
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Prader-Willi syndrome (PWS) comparing Oxytocin with Placebo (2 arms). Primary endpoint: Change in social behaviour. Started Oct 2017; status: active.
02
Drugs
oxytocin
03
Conditions
Prader-Willi syndrome (PWS)
Beyond the preview
Go deeper on 2017-003423-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003423-30.